US IPO Weekly Recap: Anthropic files for potentially record-breaking IPO

LongbridgeAII'm LongbridgeAI. Here is the key information I extracted
- Anthropic filed an S-1 for an upcoming IPO that could potentially raise $75 billion or more, making it potentially the largest IPO ever.
- During the week, OPay raised $304 million, Bambusa Therapeutics raised $169 million, and Aspen Neuroscience raised $141 million through public offerings.…
Disclaimer

Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from Anthropic (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever.

Nigeria-focused fintech OPay (OPAY) priced at the low end of the range to raise $304 million at a $4.0 billion market cap. Cornerstone investors committed to nearly 90% of the offering, with Standard Bank kicking in up to an additional $200 million in a private placement. OPay boasts that it is the #1 finance app in Africa and the Middle East based on MAUs, offering digital wallets, debit cards, savings products, and peer-to-peer and merchant payments. It is the latest in a string of Africa-linked IPOs; however, in a highly unusual case, OPay unexpectedly did not begin trading on Friday.

Immunology and inflammation biotech Bambusa Therapeutics (BBTX) priced its upsized IPO at the midpoint to raise $169 million at an $856 million market cap. A developer of long-acting bispecific antibodies, Bambusa’s lead candidate, BBT001, targets IL-4Rα and IL-31. It is in Phase 1 trials for atopic dermatitis, where it reported initial proof-of-concept data in July 2026, and has an ongoing Phase 2a trial in China for chronic spontaneous urticaria. Bambusa Therapeutics finished the week down 6.3%.

Parkinson’s disease biotech Aspen Neuroscience (ASPE) priced at the low end of the range to raise $141 million at a $462 million market cap. Aspen is developing autologous induced pluripotent stem cell (iPSC)-derived therapies for neurodegenerative diseases. Its lead candidate, sasineprocel, is a single-dose cell therapy made from cells taken from a patient’s own skin biopsy, designed to replace the dopaminergic neurons lost in Parkinson’s disease. Aspen Neuroscience finished the week down 0.7%.

Atlanta area bank Georgia Banking Company (GBC) completed its direct listing on the Nasdaq. Backed by Patriot Financial Partners, Fortress Investment Group, and AllianceBernstein, the company provides a variety of commercial and community banking services in the Atlanta area through 10 full-service banking offices and three loan production offices. It finished the week at $38.38, or 27.9% above its last private round of $30.

Four IPOs submitted initial filings this week, headlined by AI model developer Anthropic. We estimate that it could raise $75 billion or more in a mid-November listing, potentially eclipsing SpaceX as the largest IPO ever. After filing an initial prospectus, the company must wait 15 days before publicly marketing the deal, meaning investors will have to wait at least one more week before seeing the roadshow. In the meantime, Anthropic could submit an amended filing detailing its highly anticipated third quarter results.

IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 10/29/2026, the Renaissance IPO Index was up 11.1% year-to-date, while the S&P 500 was up 13.8%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Astera Labs (ALAB) and SpaceX (SPCX). The Renaissance International IPO Index was up 12.6% year-to-date, while the ACWX was up 12.4%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Galderma and Kioxia (Toshiba Memory).

Source: RenaissanceCapital The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.